Biofrontera AG, the Leverkusen-headquartered German biopharmaceutical company focusing on sun-induced skin cancer has announced that there have been no new operational developments or matters which have arisen in relation to the ongoing approval processes or other operational aspects of the company.
Prof. Dr Hermann Lübbert, the Chairman of the company’s Management Board
Business development activities remain in accordance with previous announcements in our regular financial reports, ad hoc releases and the recently published securities prospectus, Biofrontera said on Wednesday.
The company further added that the announcement also applies to the US approval application for the skin-cancer drug Ameluz in the treatment of actinic keratosis.
In line with the company’s timetable, Biofrontera says it submitted on Tuesday the “120-day safety update” which also includes clinical and cosmetic follow-up results of our Phase III trial for field treatment.
According to Biofrontera, the clinical part of the Phase III study for the European approval process for the treatment of basal cell carcinomas is expected to be complete this month, with preliminary results currently expected to be available as planned before the end of the year.